Catherine Schairer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1279089/publications.pdf

Version: 2024-02-01

71 papers 6,466 citations

33 h-index 95266 68 g-index

72 all docs 72 docs citations

times ranked

72

8330 citing authors

#	Article	IF	Citations
1	Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1575-1581.	2.5	1
2	Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project. International Journal of Cancer, 2020, 147, 675-685.	5.1	24
3	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women. Hepatology, 2020, 72, 535-547.	7.3	23
4	Obesity and related conditions and risk of inflammatory breast cancer: a nested case–control study. Breast Cancer Research and Treatment, 2020, 183, 467-478.	2.5	6
5	Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. Breast Cancer Research and Treatment, 2020, 184, 543-558.	2.5	6
6	Exogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and theÂUK Biobank. British Journal of Cancer, 2020, 123, 316-324.	6.4	20
7	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.9	35
8	Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. Journal of the National Cancer Institute, 2019, 111, 1263-1278.	6.3	60
9	Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. Breast Cancer Research and Treatment, 2019, 176, 407-417.	2.5	10
10	Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001–2015). Breast Cancer Research and Treatment, 2019, 175, 755-764.	2.5	7
11	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. International Journal of Cancer, 2019, 145, 58-69.	5.1	28
12	Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. British Journal of Cancer, 2018, 118, 1005-1012.	6.4	142
13	Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 396-406.	1.7	23
14	Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Research and Treatment, 2018, 169, 607-614.	2.5	7
15	Family History of Cancer and Risk of Biliary Tract Cancers: Results from the Biliary Tract Cancers Pooling Project. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 348-351.	2.5	5
16	Autoimmune diseases and breast cancer risk by tumor hormoneâ€receptor status among elderly women. International Journal of Cancer, 2018, 142, 1202-1208.	5.1	18
17	Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. American Journal of Gastroenterology, 2018, 113, 1494-1505.	0.4	70
18	Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 862-868.	2.5	25

#	Article	IF	CITATIONS
19	Body Size Indicators and Risk of Gallbladder Cancer: Pooled Analysis of Individual-Level Data from 19 Prospective Cohort Studies. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 597-606.	2.5	33
20	Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women. Cancer Research, 2017, 77, 918-925.	0.9	91
21	Reliability of medical records in diagnosing inflammatory breast cancer in Egypt. BMC Research Notes, 2017, 10, 126.	1.4	8
22	White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Breast Cancer Research, 2017, 19, 94.	5.0	9
23	Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Internal Medicine, 2016, 176, 816.	5.1	1,000
24	Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Cancer Research, 2016, 76, 6076-6083.	0.9	119
25	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	1.6	349
26	Quantifying the Role of Circulating Unconjugated Estradiol in Mediating the Body Mass Index–Breast Cancer Association. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 105-113.	2.5	26
27	Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. Thyroid, 2016, 26, 306-318.	4.5	148
28	Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, 2004–2008. BioMed Research International, 2015, 2015, 1-9.	1.9	18
29	Anthropometry and head and neck cancer:a pooled analysis of cohort data. International Journal of Epidemiology, 2015, 44, 673-681.	1.9	32
30	NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prevention Research, 2015, 8, 1156-1162.	1.5	74
31	Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1398-1406.	2.5	47
32	Association between Class III Obesity (BMI of 40–59 kg/m2) and Mortality: A Pooled Analysis of 20 Prospective Studies. PLoS Medicine, 2014, 11, e1001673.	8.4	299
33	Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data. Cancer Causes and Control, 2014, 25, 959-968.	1.8	21
34	Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers. Journal of the National Cancer Institute, 2013, 105, 1373-1384.	6.3	58
35	Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in E gypt and T unisia. Cancer Medicine, 2013, 2, 178-184.	2.8	19
36	Association of Inflammatory and Noninflammatory Breast Cancer with Socioeconomic Characteristics in the Surveillance, Epidemiology, and End Results Database, 2000–2007. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 155-165.	2.5	25

#	Article	IF	CITATIONS
37	Estrogen Metabolism and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2012, 104, 326-339.	6.3	174
38	Considerations in setting up and conducting epidemiologic studies of cancer in middle―and lowâ€income countries: the experience of a case–control study of inflammatory breast cancer in N orth A frica in the past 10 years. Cancer Medicine, 2012, 1, 338-349.	2.8	16
39	Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008. Breast Cancer Research and Treatment, 2012, 134, 1257-1268.	2.5	46
40	Alcohol and breast cancer risk in postmenopausal women: The PLCO experience Journal of Clinical Oncology, 2012, 30, 1521-1521.	1.6	0
41	Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 129, 117-124.	2.5	26
42	Hormone-related Risk Factors and Postmenopausal Breast Cancer Among Nulliparous Versus Parous Women: An Aggregated Study. American Journal of Epidemiology, 2011, 173, 509-517.	3.4	29
43	Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. Hormones and Cancer, 2010, 1, 100-111.	4.9	19
44	Menopausal Hormone Therapy and Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 196-203.	2.5	96
45	Breast Cancer Relative Hazard Estimates From Case–Control and Cohort Designs With Missing Data on Mammographic Density. Journal of the American Statistical Association, 2008, 103, 976-988.	3.1	6
46	Comparative Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers. Journal of the National Cancer Institute, 2007, 99, 1248-1256.	6.3	38
47	Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Research and Treatment, 2007, 106, 439-451.	2.5	94
48	Weight, Height, and Body Mass Index and Risk for Ovarian Cancer in a Cohort Study. Annals of Epidemiology, 2006, 16, 869-876.	1.9	18
49	Epidemiology of Inflammatory Breast Cancer (IBC)1. Breast Disease, 2006, 22, 9-23.	0.8	201
50	Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer, 2006, 107, 1075-1083.	4.1	32
51	Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. International Journal of Cancer, 2006, 119, 2398-2401.	5.1	70
52	Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. International Journal of Cancer, 2006, 119, 2402-2407.	5.1	59
53	Suicide After Breast Cancer: an International Population-Based Study of 723 810 Women. Journal of the National Cancer Institute, 2006, 98, 1416-1419.	6.3	106
54	Serum Concentrations of Estrogens, Sex Hormone Binding Globulin, and Androgens and Risk of Breast Hyperplasia in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1660-1665.	2.5	18

#	Article	IF	CITATIONS
55	Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1724-1731.	2.5	80
56	Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients. Journal of the National Cancer Institute, 2004, 96, 1311-1321.	6.3	239
57	Medication use and risk of ovarian carcinoma: A prospective study. International Journal of Cancer, 2004, 108, 281-286.	5.1	54
58	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. International Journal of Cancer, 2004, 108, 773-779.	5.1	81
59	Progesterone receptors - animal models and cell signaling in breast cancer: Implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Research, 2002, 4, 244-8.	5.0	8
60	Fruit and vegetable intakes and the risk of colorectal cancer in the Breast Cancer Detection Demonstration Project follow-up cohort. American Journal of Clinical Nutrition, 2002, 75, 936-943.	4.7	129
61	Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes and Control, 2001, 12, 103-110.	1.8	94
62	Dietary Fat, Fat Subtypes, and Breast Cancer in Postmenopausal Women: a Prospective Cohort Study. Journal of the National Cancer Institute, 2000, 92, 833-839.	6.3	95
63	Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk. JAMA - Journal of the American Medical Association, 2000, 283, 485.	7.4	901
64	Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes and Control, 1999, 10, 253-260.	1.8	233
65	A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes and Control, 1997, 8, 130-138.	1.8	71
66	Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohort. , 1996, 67, 327-332.		292
67	Cancer incidence and mortality in women receiving estrogen and estrogenâ€progestin replacement therapy—longâ€ŧerm followâ€up of a Swedish cohort. International Journal of Cancer, 1996, 67, 327-332.	5.1	1
68	Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United) Tj ETQq0 0) 0 [gBT /C	werlock 10 Tf
69	Heterogeneity of the Effect of Family History on Breast Cancer Risk. Epidemiology, 1991, 2, 276-284.	2.7	61
70	RACIAL DIFFERENCES IN BLADDER CANCER RISK: A CASE-CONTROL STUDY. American Journal of Epidemiology, 1988, 128, 1027-1037.	3.4	25
71	Methylxanthines and breast cancer. International Journal of Cancer, 1987, 40, 469-473.	5.1	31